Search results for "Placebos"

showing 10 items of 65 documents

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Effects of HIV, antiretroviral therapy and prebiotics on the active fraction of the gut microbiota

2018

In a recent blinded randomized study, we found that in HIV-infected individuals a short supplementation with prebiotics (scGOS/lcFOS/glutamine) ameliorates dysbiosis of total gut bacteria, particularly among viremic untreated patients. Our study goal was to determine the fraction of the microbiota that becomes active during the intervention and that could provide additional functional information.A total of six healthy individuals, and 16 HIV-infected patients comprising viremic untreated patients (n = 5) and antiretroviral therapy-treated patients that are further divided into immunological responders (n = 7) and immunological nonresponders (n = 4) completed the 6-week course of prebiotic …

DNA Bacterial0301 basic medicine030106 microbiologyImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsGut floramedicine.disease_causeDNA Ribosomallaw.inventionPlacebos03 medical and health sciencesPharmacotherapyImmune systemRandomized controlled triallawRNA Ribosomal 16SmedicineCluster AnalysisHumansImmunology and AllergyPhylogenyBacteriabiologybusiness.industrySequence Analysis DNAMiddle Agedmedicine.diseasebiology.organism_classificationAntiretroviral therapyGastrointestinal MicrobiomeGlutaminePrebiotics030104 developmental biologyInfectious DiseasesAnti-Retroviral AgentsImmunologybusinessDysbiosisFollow-Up StudiesAIDS
researchProduct

Effects of pulsed high-frequency electromagnetic fields on the neuroendocrine system.

1998

The influence of pulsed high-frequency electromagnetic fields emitted from a circularly polarized antenna on the neuroendocrine system in healthy humans was investigated (900 MHz electromagnetic field, pulsed with 217 Hz, average power density 0.02 mW/cm<sup>2</sup>). Nocturnal hormone profiles of growth hormone (GH), cortisol, luteinizing hormone (LH) and melatonin were determined under polysomnographic control. An alteration in the hypothalamo-pituitary-adrenal axis activity was found with a slight, transient elevation in the cortisol serum level immediately after onset of field exposure which persisted for 1 h. For GH, LH and melatonin, no significant effects were found under…

Electromagnetic fieldAdultMalemedicine.medical_specialtyHypothalamo-Hypophyseal SystemAdolescentHydrocortisoneEndocrinology Diabetes and MetabolismStimulus (physiology)NocturnalGrowth hormoneMelatoninPlacebosCellular and Molecular NeuroscienceEndocrinologyElectromagnetic FieldsInternal medicineAdrenal GlandsmedicineHumansMelatoninEndocrine and Autonomic SystemsChemistryHuman Growth HormoneElectroencephalographyLuteinizing HormoneEndocrinologyLuteinizing hormoneSleepSleep eegHormonemedicine.drugNeuroendocrinology
researchProduct

The effect of orally administered probiotic Lactobacillus reuteri -containing tablets in peri-implant mucositis: a double-blind randomized controlled…

2015

Background and Objectives Probiotics create a biofilm and protect the oral tissues against the action of periodontal pathogenic bacteria. The aim of this study was to evaluate the effects of the oral probiotic Lactobacillus reuteri Prodentis upon the peri-implant health of edentulous patients with dental implants and peri-implant mucositis, establishing comparisons vs implants without peri-implant disease. Material and Methods A double-blind, placebo-controlled, prospective cross-over study was made. The patients were all edentulous and were divided into two groups, (A) no peri-implant disease, and (B) peri-implant mucositis affecting one or more implants. Patients with peri-implantitis wer…

Limosilactobacillus reuteriMaleMucositismedicine.medical_specialtyPeri-implant mucositisDentistryPlaceboGastroenterologylaw.inventionPlacebosProbioticDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineMucositisHumansProspective StudiesProspective cohort studyAgedCross-Over Studiesbiologybusiness.industryProbioticsMiddle Agedmedicine.diseasebiology.organism_classificationCrossover studyLactobacillus reuteriDental ImplantationTreatment OutcomeCytokinesPeriodonticsFemalebusinessTabletsJournal of Periodontal Research
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

2021

On behalf of MAST4HEALTH consortium: et al.

Male0301 basic medicine*NAFLD/NASH[SDV]Life Sciences [q-bio]MathematicsofComputing_GENERALGut floraGastroenterologyBody Mass Indexlaw.inventionPlacebos*metabolomicsLiver diseaseRandomized controlled trialNon-alcoholic Fatty Liver DiseaseFibrosislawNonalcoholic fatty liver disease*microbiota dysbiosisComputingMilieux_MISCELLANEOUSGreecebiologyMastic ResinMastihaNASHTheoryofComputation_GENERALMiddle Agedmetabolomics3. Good healthItalyLiverFemaleSerbiaMRIBiotechnologyAdultmedicine.medical_specialty*MRIPlacebo03 medical and health sciencesDouble-Blind MethodNAFLDInternal medicinemedicineHumansObesityAged030109 nutrition & dieteticsbusiness.industrymedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeClinical trialmicrobiota dysbiosis030104 developmental biologyDietary SupplementsDysbiosisComputingMilieux_COMPUTERSANDSOCIETYbusinessDysbiosis*MastihaFood Science
researchProduct

Supplementation with micronutrients and schistosomiasis: systematic review and meta-analysis

2019

Schistosomiasis is a parasitic disease caused by helminths of the genus Schistosoma with two presentations; one intestinal and another urinary; which depend on the specie of Schistosoma. One of the species that can produce intestinal schistosomiasis is Schistosoma mansoni, and the specie that produces urinary schistosomiasis is Schistosoma haematobium. Infection can be aggravated by a deficient nutritional status, which negatively impacts the immune system and increases susceptibility to infection. The main objective of this meta-analysis is to determine if a relationship exists between multimicronutrient supplementation and the reduction of infestation with Schistosoma mansoni and Schistos…

Male0301 basic medicineAdolescent030231 tropical medicine030106 microbiologyNutritional StatusSchistosomiasisReviewMicrobiologyPlacebosSchistosomiasis haematobia03 medical and health sciences0302 clinical medicineparasitic diseasesmedicineAnimalsHumansHelminthsMicronutrientsChildSchistosomaSchistosoma haematobiumbiologyPublic Health Environmental and Occupational HealthSchistosoma mansoniGeneral Medicinebiology.organism_classificationmedicine.diseaseMicronutrientSchistosomiasis mansoniInfectious DiseasesChild PreschoolMeta-analysisParasitic diseaseImmunologySchistosoma haematobiumFemaleParasitologySchistosoma mansoniPathogens and Global Health
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.

2015

Background Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. Aim To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). Methods This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome meas…

MaleColorectal cancerResistancelcsh:MedicineAdministration OralArtesunatePilot ProjectsPharmacologyGastroenterologyPlacebosNeutropaeniachemistry.chemical_compoundCancerlcsh:R5-920medicine.diagnostic_testGeneral MedicineImmunohistochemistryArtemisininsDihydroartemisininTreatment OutcomeTolerabilityOriginal ArticleFemalelcsh:Medicine (General)Colorectal NeoplasmsKi67medicine.medical_specialtyRandomizationPlaceboGeneral Biochemistry Genetics and Molecular BiologyDouble-Blind MethodMedian follow-upInternal medicineBiopsymedicineBiomarkers TumorHumansAgedDemographyStaining and Labelingbusiness.industrylcsh:Rmedicine.diseaseColorectal cancerSurvival AnalysisCarcinoembryonic AntigenMalariaClinical trialKi-67 AntigenchemistryArtesunateCommentarybusinessEBioMedicine
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct